|
UK grants first IPS cell patent to iPierian |
|
The new IPS cell patent is entitled "Human pluripotent stem cells produced by the introduction of Oct3/4, Sox2, and Klf4 genes, along with a c-Myc gene or histone deacetylase inhibitor, into post." Here are the first three claims from (note) the application as published by the EPO. (EESCN accepts no liability for any error).
1. Human pluripotent stem cells induced from undifferentiated stem cells present in human postnatal tissue and having in vitro long-term self-renewable ability and the pluripotency to differentiate into ectoderm, mesoderm and endoderm.
2. Human pluripotent stem cells established from human postnatal tissue by the introduction of each of an 0ct314, Sox2 and K1f4 gene and either the c-Myc gene or a histone deacetylase inhibitor, said human postnatal tissue comprising undifferentiated stem cells in which each gene of Tert, Nanog, Oct3/4 and Sox 2 has not undergone epigenetic inactivation.
3. Human pluripotent stem cells derived from human postnatal tissue by introducing thereinto either Oct3/4, Sox2 and K1f4, or Oct3/4, Sox2 and K1f4 as well as c-Myc or a histone deacetylase inhibitor"
4..... We'd be interested to hear your views on the new iPierian patent and other IPS patent applications.
|
